Table 3. Treatment and follow-up outcomes of 14 patients with posterior scleritis.
| Variable | Number (%)/mean ± SD |
|---|---|
| Treatment | |
| Topical antibiotics and steroids | 13 (92.9) |
| Topical NSAIDs | 4 (28.6) |
| Systemic steroids | 11 (78.6) |
| Systemic NSAIDs | 2 (14.3) |
| Systemic immunosuppressants | 4 (28.6) |
| Cyclosporine | 2 (14.3) |
| Cyclophosphamide | 1 (7.1) |
| Methotrexate | 1 (7.1) |
| Systemic biologics | 1 (7.1) |
| Intravitreal dexamethasone injection | 2 (14.3) |
| Vitrectomy | 1 (7.1) |
| Recurrence (eyes, events) | 3 (21.4%, 1.6±0.7) |
| Follow-up duration (months) | 31.6±39.2 |
| Final logMAR BCVA | 0.6±1.0 (P=0.878*) |
*, comparison of initial and final visual acuity using Wilcoxon’s signed rank test. SD, standard deviation; NSAID, non-steroidal anti-inflammatory drugs; logMAR, logarithm of the minimum angle of resolution; BCVA, best-corrected visual acuity.